Technology
AXA Global Business Services Embarks on a New Era of Transformation as it Celebrates 30 Years in India
Published
2 years agoon
By
AXA GBS marks three decades in India, expanding across Bangalore, Pune, UK, and Morocco. It serves over 35 AXA entities in 14 countries, delivering innovation, operational excellence and high customer satisfaction, and has an employee footprint of over 4,000 employees globally.AXA GBS is transitioning from traditional transactional work to a high-value, output-based model, further demonstrated by its new state-of-the-art facility in Pune, focusing on technology, automation, data analytics and AI.AXA GBS has achieved a higher customer satisfaction rate, and with a focus on upskilling, is investing heavily in role-based learning academies, an 88% employee engagement score and 90% retention rate, reflecting a commitment to people-centric growth and global collaboration.
BENGALURU, India and PUNE, India, Feb. 13, 2025 /PRNewswire/ — AXA Global Business Services (AXA GBS), a part of the AXA Group, proudly celebrates its 30 years of operations in India. The occasion was marked by a celebratory townhall in both Pune and Bangalore, with the AXA GBS Executive Committee members joining CEO, Michele Rochefort at the event.
With a global employee footprint of over 4,000 professionals across Bangalore, Pune, UK, and Morocco, AXA GBS continues to expand its presence while driving innovation, employee experience, operational excellence and strong customer satisfaction.
AXA GBS currently co-partners with over 35 AXA entities across 14 countries. It blends expertise in technology services such as application development & maintenance, data analytics, artificial intelligence, and industrial automation, along with traditional business process services including language support to deliver tangible value across AXA’s global ecosystem. This milestone also marks a significant transition for AXA GBS to being a trusted advisor to AXA entities driven by a high-value, output-based operating model.
“At AXA GBS, we love to dare. We are looking within first, cannibalizing our existing business model through a bold program of intelligent automation and digitalization. We are looking to enhance our traditional operational services with a powerful combination of automation and technology, enhancing the value for AXA entities globally. With a strategic focus on driving organic growth and scaling existing services, we are confident of providing flexibility to AXA entities, unlocking collective value for AXA Group. We are investing heavily in upskilling our employees, empowering them to build their capabilities to complement their wealth of domain expertise. We are scaling operational excellence by investing in tools, platforms, and integrated systems to support AXA entities seamlessly, to be consistently impactful advisors. As an integral part of the AXA Group, AXA GBS has extensive domain knowledge and we are well placed to own, drive and deliver results for our various global entities. Our focus also remains on retaining intellectual property and value within AXA. I am confident that our strategic transformation will yield great results for our Entities, Processes, and People. 30 years combined with AXA Group’s 40th year anniversary in April is a testament to our long-standing legacies entwining to deliver value for the Group,” said Michele Rochefort, Chief Executive Officer, AXA Global Business Services.
AXA GBS’s dedication to operational excellence is reflected in its increased customer satisfaction rate and net promoter score in the past one year. AXA GBS has demonstrated commitment and expertise in forging strong and trusted relationships with AXA’s global teams.
“With a focus on exceptional customer satisfaction, we have launched an integrated service catalogue, ensuring AXA entities have a holistic view of what we can do for them. With a smooth customer relationship management platform at the back-end, we are investing more time to co-create with our entities to open doors of innovation and excellence,” said Timothy Auger, Chief Customer & Transition Officer, AXA Global Business Services.
A newly opened, state-of-the-art facility in Pune underscores AXA GBS’s commitment to fostering a great place to work poised to deliver enhanced service delivery and cutting-edge innovation, while promoting a collaborative, inclusive workspace. Furthermore, as a skills-based organization, it fosters a high-performing and engaged workforce with an 88% employee engagement score and an impressive 90% retention rate, achieved through robust role-based learning academies.
“Our people are our exceptional talent engine – our secret sauce! Their dedication and talent drive our success and enable us to be consistently impactful advisors to AXA entities. We are committed to making AXA GBS a “Skills-First” organization, and ensuring every employee has a career path aligned to their personal growth and career ambitions – where they can truly own their career,” said Isabelle Isnard, Chief People and Communications Officer, AXA Global Business Services.
“Last year alone, AXA GBS had over 67% of our employees volunteer for over 42 corporate social responsibility programs across the country. Our commitment to communities around us for inclusive protection and environment will continue; but we are also investing in ensuring it is a promise made by our people – 5% of goals in our employee performance is dedicated to community volunteering work; and we are on the path to combining this dedicated time to be skills-based volunteering to ensure there is more purpose to work and a flavor for learning. This is a particularly special achievement for us – our goals in advancing in the fields of automation, data analytics, and AI, along with other technologies, is beautifully balanced with and grounded in our drive to do good for our people, communities, and environment. And these numbers validate that,” said Rahul Sinha, Chief Data Analytics and AI Officer & Executive Sponsor – CSR at AXA Global Business Services.
As AXA GBS looks ahead to its new chapter, it remains steadfast in pushing boundaries and embracing emerging technologies to drive AXA’s global ambitions. Harnessing its talented workforce and evolving service offerings, it stands poised to shape the future of insurance and beyond, setting new benchmarks for innovation, collaboration and measurable value creation.
LinkedIn:
https://in.linkedin.com/company/axa-global-business-services-axa-gbs
ABOUT AXA GLOBAL BUSINESS SERVICES
AXA Global Business Services (AXA GBS) is a part of the AXA Group, a leading multinational insurance firm headquartered in Paris, France. Located in India, Morocco, and UK with more than 4000 employees, the organization provides essential business support services across various functions such as finance, human resources, IT, and procurement to AXA entities worldwide. As part of AXA’s commitment to tech-driven innovation, AXA GBS plays a pivotal role in fostering cutting-edge technological solutions and driving digital transformation across the organization.
ABOUT THE AXA GROUP
The AXA Group is a worldwide leader in insurance and asset management, with 147,000 employees serving 94 million clients in 50 countries. In 2023, IFRS17 revenues amounted to Euro 102.7 billion and IFRS17 underlying earnings to Euro 7.6 billion. AXA had Euro 946 billion in assets under management, including assets managed on behalf of third parties, as of December 31, 2023.
The AXA ordinary share is listed on compartment A of Euronext Paris under the ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA). AXA’s American Depository Share is also quoted on the OTC QX platform under the ticker symbol AXAHY.
The AXA Group is included in the main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD. It is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment.
IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES
Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as “expects”, “anticipates”, “may”, “plan” or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, “would” and “could”. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA’s control, and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Readers are therefore cautioned that a variety of factors could influence and cause actual results to differ from those anticipated or implied in any forward-looking statements, in some instances materially. Each forward-looking statement speaks only
at the date of this press release. Please refer to Part 5 – “Risk Factors and Risk Management” of AXA’s Universal Registration Document for the year ended December 31, 2023 (the “2023 Universal Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations. This press release is not intended to and does not contain or constitute an offer to purchase or sell AXA’s securities. In addition, this press release refers to certain non-GAAP financial measures, or alternative performance measures (“APMs”), used by Management in analyzing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA’s results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS. “Underlying earnings”, “underlying earnings per share”, “underlying return on equity”, “combined ratio” and “debt gearing” are APMs as defined in ESMA’s guidelines and the AMF’s related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Half-Year Financial Report as of June 30, 2024, on the pages indicated under the heading “IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES”. For further information on the above-mentioned and other non-GAAP financial measures used in this press release, see the Glossary set forth in AXA’s 2023 Universal Registration Document.
Photo: https://mma.prnewswire.com/media/2619489/AXA_Michele_Rochefort.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/axa-global-business-services-embarks-on-a-new-era-of-transformation-as-it-celebrates-30-years-in-india-302375701.html
You may like
Technology
CHIME and ScaleHealth Announce Joint Venture to Expand Healthcare’s Innovation Ecosystem
Published
55 minutes agoon
October 27, 2026By
ScaleHealth, powered by CHIME, creates new pathways connecting healthcare leaders, innovators, technology partners, and investors to accelerate the future of digital health.
ANN ARBOR, Mich., Oct. 27, 2026 /PRNewswire/ — The College of Healthcare Information Management Executives (CHIME) today announced a strategic joint venture with ScaleHealth, Inc. to create ScaleHealth, powered by CHIME, LLC, a new innovation ecosystem designed to connect healthcare’s most pressing challenges with the innovators, leaders, organizations, and partners capable of solving them. By combining CHIME’s trusted digital health community with ScaleHealth’s expansive innovation ecosystem, the venture creates a unique environment where healthcare organizations, entrepreneurs, established technology companies, and investors can discover, connect, validate, and advance the ideas shaping the future of healthcare.
For 35 years, CHIME has evolved alongside the digital health leaders it serves. What began as a community centered on healthcare CIOs has grown into a global network of digital health leaders supported through education, events, research, policy initiatives, media platforms, executive collaboration, and professional communities. The creation of ScaleHealth, powered by CHIME represents the next chapter in that evolution, expanding CHIME’s ecosystem to include the innovators, entrepreneurs, and emerging technology companies helping define what comes next in healthcare.
As healthcare organizations face increasing pressure to improve outcomes, strengthen operations, address workforce challenges, improve cybersecurity, and realize the promise of emerging technologies including artificial intelligence, the need for stronger connections across the innovation ecosystem has never been greater. ScaleHealth, powered by CHIME was created to help build those connections.
“CHIME has spent 35 years bringing together the leaders responsible for solving healthcare’s most important technology and transformation challenges,” said Russ Branzell, President and CEO of CHIME. “As the pace of innovation continues to accelerate, we have an opportunity to expand that trusted community even further. ScaleHealth, powered by CHIME, extends our ecosystem to include entrepreneurs, innovators, investors, and emerging technology companies so that healthcare leaders can engage earlier, collaborate more effectively, and help shape the innovations that will define the future of healthcare.”
The opportunity emerged through CHIME’s growing innovation programming, particularly its Innovation Summit series, where healthcare leaders and technology companies increasingly expressed a desire to engage more directly with innovators and entrepreneurial organizations. At the same time, startups and growth-stage companies were seeking trusted pathways into healthcare and stronger connections to leaders who understand the industry’s real-world operational challenges.
“Healthcare has no shortage of innovation. The challenge is creating trusted pathways that connect innovators with the healthcare leaders who understand the industry’s most urgent problems,” said Taylor McPartland, CEO of ScaleHealth and leader of the new venture. “By combining ScaleHealth’s innovation ecosystem with CHIME’s trusted community of digital health leaders, we’re creating an environment where meaningful connections can lead to validation, partnership, and real-world impact. This is about bringing together everyone who has a role to play in the future of healthcare innovation and helping them move great ideas forward.”
Unlike traditional accelerators, startup showcases, or innovation marketplaces, ScaleHealth, powered by CHIME is designed as a trusted innovation ecosystem. Healthcare organizations bring forward meaningful challenges. Innovators and startups contribute cutting-edge ideas and technologies. Established technology organizations bring expertise, infrastructure, and scale. Investors provide capital and growth pathways. Together, these stakeholders create an environment where innovation can move from discovery and connection to validation, partnership, and measurable impact.
“Throughout its history, CHIME has grown by bringing the right people together around the challenges that matter most,” said Tressa Springmann, Senior Vice President and Chief Information and Digital Officer at LifeBridge Health and Chair of the CHIME Foundation Board of Directors. “Today, innovation is essential to every aspect of healthcare transformation. ScaleHealth, powered by CHIME extends that trusted community into a broader innovation ecosystem, creating new opportunities for healthcare leaders, entrepreneurs, technology partners, and investors to collaborate, learn from one another, and accelerate meaningful progress across healthcare.”
The venture reflects CHIME’s belief that the next era of digital health will be co-created by healthcare leaders, technology partners, entrepreneurs, investors, and innovators working together to solve the challenges that matter most. By creating a trusted environment for discovery, collaboration, validation, and advancement, ScaleHealth, powered by CHIME aims to become the connective layer between healthcare’s needs and the innovation being built to address them.
About CHIME
The College of Healthcare Information Management Executives (CHIME) is the leading professional organization for digital health executives and leaders. CHIME provides a trusted, collaborative environment where members and partners connect, share best practices, advance professional development, and advocate for the effective use of information and technology to improve health and care in the communities they serve. For more information, please visit chimecentral.org.
For media inquiries, please contact:
Contact
Calli Dretke
Executive Vice President & Chief Digital and Marketing Officer
CHIME
734.412.6255
cdretke@dhinsights.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/chime-and-scalehealth-announce-joint-venture-to-expand-healthcares-innovation-ecosystem-302921260.html
SOURCE College of Healthcare Information Management Executives (CHIME)
Technology
In HelloNation, Prenatal Imaging Expert Erika Lambright Explains Ultrasound Differences Between 2D, 3D, And 4D Imaging
Published
55 minutes agoon
October 27, 2026By
The article outlines how each type of pregnancy ultrasound supports fetal development and family understanding.
DENISON, Texas, Oct. 27, 2026 /PRNewswire/ — What is the difference between 2D, 3D, and 4D ultrasound imaging during pregnancy? HelloNation has published an article that clearly explains the differences between ultrasound and other prenatal imaging modalities and how each supports fetal development.
The HelloNation article explains that a 2d ultrasound is the most common form of prenatal imaging used during routine pregnancy ultrasound appointments. It produces flat, black-and-white images that allow medical providers to assess fetal development, monitor growth, and evaluate vital structures. The article notes that 2D ultrasound plays a central role in identifying potential concerns early and remains the foundation of prenatal diagnostic imaging.
According to the article, a 3d ultrasound builds on the same technology but creates a more detailed still image with depth. This form of prenatal imaging allows families to see clearer views of the baby’s face, hands, and feet. While 3d ultrasound can support certain medical evaluations, the article describes its primary value as helping parents better visualize fetal development in a more lifelike way.
The article further describes how a 4D ultrasound adds motion to the 3d ultrasound image. This allows families to view real-time video of the baby moving, stretching, or making facial expressions. The article explains that this type of pregnancy ultrasound creates a more engaging experience and helps strengthen the emotional connection, while still using the same safe, noninvasive prenatal imaging technology.
The HelloNation article emphasizes that understanding ultrasound differences helps families set clear expectations before imaging sessions. Each type of pregnancy ultrasound serves a distinct purpose. 2D ultrasound focuses on medical accuracy and fetal development monitoring, while 3D and 4D ultrasound provide enhanced visualization and connection. The article highlights that medical professionals typically rely on 2D ultrasound for diagnostic purposes, while 3D and 4D ultrasound are often optional.
The article also notes that several factors can affect the quality of prenatal imaging results. Baby position, gestational age, and fluid levels all play a role in how clearly images appear, especially during 3D and 4D ultrasound sessions. The article explains that providers often guide families on the best timing for ultrasound visits during pregnancy to improve image clarity and achieve better results.
Prenatal Imaging Experts emphasize through the article that learning about ultrasound differences can reduce uncertainty and help families feel more prepared. By understanding how each type of prenatal imaging contributes to monitoring fetal development, expectant parents can approach each pregnancy ultrasound appointment with clearer expectations.
The article concludes that while 2D ultrasound remains essential for medical care, the added perspectives of 3D and 4D ultrasound offer families a broader, more personal understanding of fetal development. Together, these forms of prenatal imaging provide both clinical insight and meaningful connection throughout pregnancy.
What Is the Difference Between 2D, 3D, and 4D Ultrasounds Explained Simply features insights from Erika Lambright, Prenatal Imaging Experts of Denison, Texas, in HelloNation.
About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused digital publications and innovative “edvertising” approach, HelloNation delivers expert-driven, good-news content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities. HelloNation maintains partnerships with the U.S. Conference of Mayors and the United States First Responders Association.
View original content to download multimedia:https://www.prnewswire.com/news-releases/in-hellonation-prenatal-imaging-expert-erika-lambright-explains-ultrasound-differences-between-2d-3d-and-4d-imaging-302792440.html
SOURCE HelloNation
Technology
Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain
Published
55 minutes agoon
October 27, 2026By
Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.1
AACHEN, Germany, Oct. 27, 2026 /PRNewswire/ — Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand.
The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for retreatment, the numerical difference favoured Qutenza® but did not reach statistical significance. In the extension phase of the trial, in which up to 4 retreatments were allowed, Qutenza® achieved a statistically significantly greater reduction in API than the control treatment over weeks 2-42. Safety findings were consistent with previous Qutenza® trials and no new safety signals were observed. These data support the well-established efficacy and safety profile of Qutenza®.2,3
“Post-surgical neuropathic pain can be difficult to manage with current treatment options, and there is an urgent need for patient-centred, effective solutions. The RISE trial provides encouraging evidence that Qutenza® can deliver clinically meaningful and sustained pain reduction for up to 42 weeks, having shown a greater reduction in average pain intensity than the control,” said Prof. Patrice Forget, MD, PhD, FFPMRCA, Clinical Chair (full professor) in Anaesthesia, University of Aberdeen, and Honorary Consultant, NHS Grampian, Aberdeen, UK. “As IASP shines a global spotlight on neuropathic pain at this year’s congress, findings such as these are important to help improve outcomes for patients and reduce the burden of pain on families and healthcare systems.”
“Post-surgical neuropathic pain has been relatively understudied and continues to go under-recognised in clinical practice,” said Uli Brödl, Chief Scientific Officer, Grünenthal. “These results build on the robust body of evidence for Qutenza® and reinforce its potential to provide meaningful, long-lasting pain relief for people living with pain.”
Post-surgical neuropathic pain is a poorly recognised potential complication of surgery that can result in devastating outcomes. It affects millions of patients every year, with pain lasting for months or years post-procedure.1 It can also have a significant mental health impact, with patients reporting feeling extremely depressed or anxious, and having problems with daily activities.4
Qutenza® is already approved in Europe for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5 It is also approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.6
About the RISE trial2,3
The RISE (AV-001) trial is a Phase III multi-centre, randomised, double-blind, parallel-group trial to confirm the efficacy and safety of Qutenza 179mg cutaneous patch versus a low-dose capsaicin control patch in people with moderate to severe post-surgical neuropathic pain.
It included eligible adults with a 24-hour average pain intensity (API) score of 4 or more, a pain duration of 6 to 60 months after index surgery and a DN4 (Douleur Neuropathique 4) Interview score of 3 or more.
Participants were randomly assigned to receive treatment with either a 60-minute Qutenza patch (8%) or a low-dose capsaicin control patch (0.04%).
The trial had two primary endpoints:
Change in 24-hour API from baseline to the average score of the entire period between Week 2 and Week 12.Change in 24-hour API from baseline to the average score at Week 12.
The primary sponsor of the trial is Averitas Pharma, Inc., Grünenthal’s U.S. subsidiary.
About post-surgical neuropathic pain
Post-surgical neuropathic pain (PSNP) is defined as chronic pain with neuropathic characteristics that develops or increases after surgery and persists beyond the normal healing process. It is thought to arise, at least in part, from nerve injury and pain sensitisation associated with surgery.7
The signs and symptoms of peri- and post-surgical pain can vary based on the person and the severity of the injury caused in surgery. Reported symptoms include pain caused by stimuli that are normally painless (allodynia), abnormally increased sensitivity to pain (hyperalgesia), tingling, numbness, phantom pain and scar pain.8,9,10
About Qutenza®
In Europe, Qutenza® (capsaicin) is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5
Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.6
Qutenza® is a topical TRPV1 agonist, designed to provide neuropathic pain relief for up to three months through defunctionalisation of nociceptors and nerve fibre regeneration.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.
More information: www.grunenthal.com
Follow us on LinkedIn & Instagram
For further information, please contact:
Matt Crabb, Head of Global Communications (Interim) at Grünenthal
References
1 Gregory P & Settles K. Pract Pain Manag. 2013;13(9):1–6.
2 Wallace M et al. Efficacy of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
3 Wallace M et al. Safety and tolerability of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
4 Santos MP, Lemos F, Gomes J, Romao JM, Veiga D. Br J Pain 2024;18(1):42–56.
5 European Medicines Agency. Qutenza 179 mg cutaneous patch SmPC. Available at: https://www.medicines.org.uk/emc/product/573/smpc
6 US Food and Drug Administration. Qutenza® Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf
7 Correl D. F1000Res. 2017;6:1054.
8 Werner MU & Kongsgaard UE. Br J Anaesth. 2014;113(1):1–4.
9 Macrae WA. Br J Anaesth. 2008;101:77–86.
10 Searle RD & Simpson KH. Contin Educ Anaesth Crit Care Pain. 2010;10:12–14.
View original content:https://www.prnewswire.com/news-releases/grunenthal-presents-phase-iii-results-for-qutenza-in-post-surgical-neuropathic-pain-at-iasp-2026-world-congress-on-pain-302921015.html
SOURCE Grünenthal Group
CHIME and ScaleHealth Announce Joint Venture to Expand Healthcare’s Innovation Ecosystem
In HelloNation, Prenatal Imaging Expert Erika Lambright Explains Ultrasound Differences Between 2D, 3D, And 4D Imaging
Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoMiami Startup BOB Raises $5.5M To Build An AI-Powered Banking Platform
-
Coin Market5 days agoBitcoin ETFs bleed $635M as October slides back into the red
-
Coin Market4 days agoCysic dangles a 10% bounty, hacker pours loot into Tornado Cash
-
Coin Market5 days agoEthereum delays Glamsterdam Hoodi testnet launch over security risks
-
Coin Market5 days agoMalaysia, Thailand join Singapore’s cross-border stablecoin push
-
Technology4 days agoKin Becomes First U.S. Home Insurer to Enable WebMCP for AI Shopping
-
Technology5 days agoLunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
-
Technology4 days agoEnigmata Joins Finovifi Marketplace to Support AI Data Protection and Privacy-Preserving Analytics
